GALECTIN THERAPEUTICS INC — Director's Dealing 2011

Apr 13, 2011

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: PRO PHARMACEUTICALS INC (PRWP)
CIK: 0001133416
Period of Report: 2010-12-31

Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-03-31	Common Stock	J	301952	$0.44	Acquired	982783	Indirect
2010-06-30	Common Stock	J	358015	$0.71	Acquired	1340798	Indirect
2010-09-30	Common Stock	J	380475	$0.79	Acquired	1721273	Indirect
2010-12-31	Common Stock	J	380475	$0.9	Acquired	2101748	Indirect

Footnotes

F1: Received as a dividend on Class B Convertible Preferred Stock owned by 10X Fund, LP.

F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., such portion being equal to 10X Capital Management, LLC's (a) 20% interest in the profits of 10X Fund, L.P., (b) interest in any securities which are used to pay a 2% annual management fee to 10X Capital Management, LLC, and (c) interest in one-half of the Class B Warrants acquired by 10X Fund, L.P. in all closings other than the initial closing held on February 12, 2009, less one Class B Warrant which 10X Capital Management, LLC has committed to reallocate to investors in all prior closings until each such investor has one (1) additional Class B Warrant for each dollar invested.

F3: 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.